Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
America’s Obesity Epidemic Accelerates Amidst Rising Popularity of Ozempic
Recent agreements from former President Donald Trump aim to reduce costs on popular weight-loss drugs. This could precipitate an escalated interest in GLP-1 medications, such as Ozempic and Mounjaro. Even now, usage trends reveal variances across the United States, with certain states experiencing a sharper increase in prescriptions than others.
A report from Purple Lab, a health analytics company based in Pennsylvania, sheds light on this trend. The 2024 report analyzed insurance claims data and revealed the estimated number of prescriptions for weight-loss and diabetes medications across various states.
It’s important to note that this analysis excludes individuals who paid out-of-pocket, those using telehealth providers, compounded medication, or the uninsured. Consequently, the actual volume of prescriptions is likely even greater, reflecting a more profound shift in how these medications are perceived and utilized.
States Leading in GLP-1 Prescriptions
The findings from the report identified states where more than 15% of the population received GLP-1 prescriptions intended for weight management or diabetes management.
The highest utilization of GLP-1 medications was notably found in Southern states, the Midwest, and Appalachia. This pattern likely correlates with higher rates of obesity and diabetes prevalent in these regions.
Low-Usage States
Conversely, regions with the lowest rates of GLP-1 prescriptions tend to be coastal or located in the western part of the U.S. Hawaii stands out as the state with the fewest prescriptions overall.
Doctor Insights on GLP-1 Medications
Dr. Brett Osborn, a neurologist and expert in longevity based in Florida, frequently prescribes GLP-1 medications to his patients and himself. He highlights the evolving role of these medications.
“These agents are primarily prescribed for type 2 diabetes,” Dr. Osborn stated. “However, the tides are turning; soon, they may also be utilized more broadly for weight management among individuals without diabetes.”
Moreover, Dr. Osborn envisions that GLP-1 medications will increasingly be used to address additional health challenges. These include the prevention of vascular diseases, moderation of alcohol consumption, and support for gambling addiction. He also anticipates their potential in mitigating cognitive decline and enhancing chemotherapy treatments.
